Legislators in the USA have been discussing reforms to reduce the high cost of brand-name drugs, which are much higher in the USA than in other industrialized countries. One solution is to actively negotiate prices based on drugs’ clinical benefits. We discuss two important complexities from such an approach: drugs that have been approved for multiple indications and as part of a combination regimen.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Vokinger, K. N. et al. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe. JAMA Oncol. https://doi.org/10.1001/jamaoncol.2021.2026 (2021).
OECD. Addressing challenges in access to oncology medicines. Analytical report. OECD https://www.oecd.org/health/health-systems/Addressing-Challenges-in-Access-to-Oncology-Medicines-Analytical-Report.pdf (2020).
IQVIA Institute. Global oncology trends 2021. IQVIA https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-oncology-trends-2021/global-oncology-trends-report-2021-05-21-forweb.pdf?_=1630425102649 (2021).
Will cancer drugs get cheaper in 2020? Nat. Rev. Clin. Oncol. 17, 127–127 (2020).
Bach, P. B. Indication-specific pricing for cancer drugs. JAMA 312, 1629 (2014).
Cherla, A., Naci, H., Kesselheim, A. S., Gyawali, B. & Mossialos, E. Assessment of coverage in England of cancer drugs qualifying for US Food and Drug Administration accelerated approval. JAMA Intern. Med. 181, 490 (2021).
Webster, R. M. Combination therapies in oncology. Nat. Rev. Drug Discov. 15, 81–82 (2016).
Bach, P. B. New math on drug cost-effectiveness. N. Engl. J. Med. 373, 1797–1799 (2015).
Kesselheim, A. S., Hwang, T. J. & Avorn, J. Paying for prescription drugs in the new administration. JAMA 325, 819 (2021).
Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-Positive metastatic breast cancer. N. Engl. J. Med. 372, 724–734 (2015).
Acknowledgements
The authors are grateful to David L. Carl (University of Zurich) for assistance with a previous version of the manuscript. The work of K.N.V. is partially funded by the Swiss National Science Foundation (SNSF). The work of A.S.K. is supported by Arnold Ventures.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Vokinger, K.N., Kesselheim, A.S. Value-based pricing of drugs with multiple indications or in combinations — lessons from Europe. Nat Rev Clin Oncol 19, 1–2 (2022). https://doi.org/10.1038/s41571-021-00561-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-021-00561-6
